Truist analyst Tobey Sommer lowered the firm’s price target on Insperity (NSP) to $70 from $82 and keeps a Hold rating on the shares after its Q1 earnings miss and below-consensus guide. The firm is citing deteriorating SMB sentiment and risks of further healthcare issues, along with higher healthcare utilization, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NSP: